One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK
Peck Lin Lip,1 Huzaifa Malick,1 Kenan Damer,1 Samer Elsherbiny,1 Kanupriya M Darrad,1 Bushra Mushtaq,1 Arijit Mitra,1 Panagiota Stavrou,1 Yit Yang1,2 1Birmingham and Midland Eye Centre, City Hospital, 2School of Health and Life Sciences, Aston University, Birmingham, UK Background: The purpose of...
Guardado en:
Autores principales: | Lip PL, Malick H, Damer K, Elsherbiny S, Darrad KM, Mushtaq B, Mitra A, Stavrou P, Yang Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cfbd5243eeaf4009abdea30d4290c4e9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
por: Thapa R, et al.
Publicado: (2012) -
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir M, et al.
Publicado: (2011) -
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce G, et al.
Publicado: (2014) -
Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
por: Mushtaq B, et al.
Publicado: (2014) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008)